Bloomsbury Publishing Plc 7.8% potential upside indicated by Peel Hunt LLP

Bloomsbury Publishing Plc with ticker (LON:BMY) now has a potential upside of 7.8% according to Peel Hunt LLP.



Peel Hunt LLP set a target price of 385 GBX for the company, which when compared to the Bloomsbury Publishing Plc share price of 355 GBX at opening today (29/10/2021) indicates a potential upside of 7.8%. Trading has ranged between 240 (52 week low) and 405 (52 week high) with an average of 92,073 shares exchanging hands daily. The market capitalisation at the time of writing is £290,585,580.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abraxane, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Reyataz and Sustiva Franchise. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.